BioTuesdays

Tag - Matt O’Brien

Orchestra-Biomed-Logo

Piper starts Orchestra Biomed at OW; PT $15

Piper Sandler launched coverage of Orchestra Biomed (NASDAQ:OBIO) with an “overweight” rating and $15 price target. The stock closed at $10.30 on Feb. 23. The company develops solutions in cardiac neuromodulation and...

Humacyte

Piper cuts Humacyte to underweight; PT to $4 from $10

Piper Sandler downgraded Humacyte (NASDAQ:HUMA) to “underweight” from “overweight” and reduced its price target to $4 from $10, citing the sizable stock pullback in the sector. The stock closed at $5.37 on May 13. The...

Minerva Surgical

Analysts start Minerva Surgical at OW, OP; PT $17

Piper Sandler and SVB Leerink launched coverage of Minerva Surgical (NASDAQ:UTRS) with “overweight” and “outperform” ratings, respectively, and price targets of $17. The stock closed at $9.62 on Nov. 15. Minerva, which...

Avita Medical

Piper starts Avita Medical at OW; PT $27

Piper Sandler launched coverage of Avita Medical (NASDAQ:RCEL) with an “overweight” rating and $27 price target. The stock closed at $21.49 on March 1. Avita makes Recell, which uses a patient’s own skin to make a cell...

Surgalign Logo

Piper Sandler starts Surgalign at OW; PT $4

Piper Sandler initiated coverage of Surgalign Holdings (NASDAQ:SRGA) with an “overweight” rating and $4 price target. The stock closed at $1.70 on Feb. 1. The pure-play spine provider has made a big investment in a...

Cutera Logo

Piper starts Cutera at OW; PT $18

Piper Sandler launched coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and $18 price target. The stock closed at $11.36 on April 21. Cutera is an aesthetics provider with technologies that will perform a...

TELA Bio

Piper Jaffray starts TELA Bio at OW; PT $17

Piper Jaffray initiated coverage of TELA Bio (NASDAQ:TELA) with an “overweight” rating and $17 price target. The stock closed at $12.31 on Dec. 2. TELA is a regenerative medicine company, with products used in hernia...

Apollo Endosurgery

Piper starts Apollo Endosurgery at overweight; PT $8

Piper Jaffray launched coverage of Apollo Endosurgery (NASDAQ:LAPEN) with an “overweight” rating and $8 price target. The stock closed at $5.85 on April 12. Apollo is focused on bariatric and general surgery procedures...

Piper upgrades Nuvectra to OW; PT to $16

Piper Jaffray upgraded Nuvectra (NASDAQ:NVTR) to “overweight” from “neutral” and raised its price target to $16 from $12 after the company reported fourth quarter results. The stock closed at $11.69 on March 15. The...

Motus GI Holdings

Piper starts Motus GI at OW; PT $7

Piper Jaffray initiated coverage of Motus GI Holdings (NASDAQ:MOTS) with an “overweight” rating and $7 price target. The stock closed at $4.98 on March 9. The company’s Pure-Vu device makes the prep regimen for...